
Loading, please wait...

Loading, please wait...

In a survey of 1,254 patients with HR+/HER2− advanced breast cancer receiving CDK4/6 inhibitors, the most used agents were dalpiciclib and abemaciclib. Over 81% experienced adverse events (AEs), with leukopenia and neutropenia being most common. Differences in safety and symptom burden among CDK4/6 inhibitors underscore the need for personalized treatment selection to optimize patient outcomes and well-being.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


In a survey of 1,254 patients with HR+/HER2− advanced breast cancer receiving CDK4/6 inhibitors, the most used agents were dalpiciclib and abemaciclib. Over 81% experienced adverse events (AEs), with leukopenia and neutropenia being most common. Differences in safety and symptom burden among CDK4/6 inhibitors underscore the need for personalized treatment selection to optimize patient outcomes and well-being.
2 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday